Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: a collaborative multicentre study

Objective  To assess the efficacy and safety of transurethral needle ablation of the prostate (TUNA) for patients with symptomatic benign prostatic hyperplasia (BPH) in a multicentre trial. Patients and methods  Seventy‐six patients were recruited from five centres; all were treated with the TUNA sy...

Full description

Saved in:
Bibliographic Details
Published inBritish Journal of Urology Vol. 80; no. 1; pp. 128 - 135
Main Authors RAMON, J., LYNCH, T.H., EARDLEY, I., EKMAN, P., FRICK, J., JUNGWIRTH, A., PILLAI, M., WIKLUND, P., GOLDWASSER, B., FITZPATRICK, J.M.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Science Ltd 01.07.1997
Subjects
Aged
Aged, 80 and over
Benign prostatic hyperplasia
Catheter Ablation - methods
heat therapies
Humans
Length of Stay
Male
Middle Aged
Patient Satisfaction
Prospective Studies
prostatectomy
Prostatic Hyperplasia - surgery
Quality of Life
Sexual Dysfunction, Physiological - etiology
Sexual Dysfunction, Physiological - therapy
transurethral needle ablation
Treatment Outcome
Urinary Catheterization
Urinary Retention - etiology
Urinary Retention - therapy
Online AccessGet full text

Cover

More Information
Summary:Objective  To assess the efficacy and safety of transurethral needle ablation of the prostate (TUNA) for patients with symptomatic benign prostatic hyperplasia (BPH) in a multicentre trial. Patients and methods  Seventy‐six patients were recruited from five centres; all were treated with the TUNA system consisting of a powered radiofrequency generator and a TUNA catheter. The patients were evaluated prospectively using the international prostate symptom score (IPSS), uroflowmetry, quality‐of‐life score, and other variables, and followed for a mean of 12 months after treatment. Results  Sixty‐eight patients were available for follow‐up; TUNA produced significant improvements in the IPSS (median 22 before, to 7.5 after treatment), urinary flow rate (mean 8.7 before, to 11.6 mL/s after treatment) and quality‐of‐life score (median 5 before, to 2 after treatment) at 12 months. Conclusions  If these early promising results are maintained in the medium to long term, TUNA therapy will be a useful low‐morbidity alternative for patients with symptomatic BPH.
ISSN:0007-1331
1464-410X
DOI:10.1046/j.1464-410X.1997.00245.x